Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

Beatriz Grinsztejn(Fundação Oswaldo Cruz), Rode Secours(Gheskio Centers), RT Schooley(University of California San Diego), Marije Van Schalkwyk, Aggrey Bukuru(Joint Clinical Research Centre), PN Mugyenyi(Joint Clinical Research Centre), Linda Wieclaw(Frontier Science & Technology Research Foundation, Inc.), Courtney V. Fletcher(University of Nebraska at Omaha), Breno Santos(Hospital Nossa Senhora da Conceição), Monica Gandhi(University of California, San Francisco), Thucuma Sise, Catherine Godfrey(United States Department of State), Anchalee Avihingsanon(Chulalongkorn University), Esmelda Montalbán, Robert A. Salata(Case Western Reserve University), Beatrice Wangari Ndege(Moi University), John W. Mellors(Textron Systems (United Kingdom)), Wadzanai Samaneka(University of Zimbabwe), Javier Valencia(Asociación Civil Impacta Salud y Educación), Evelyn Hogg(Social and Scientific Systems (United States)), Peter Mugyenyi(Joint Clinical Research Centre), Patcharaphan Sugandhavesa(Chiang Mai University), Vidya Mave(Johns Hopkins University), Sharlaa Faesen(University of North Carolina at Chapel Hill), Sandra Wagner Cardoso(Instituto Evandro Chagas), Lerato Mohapi, Justin Ritz(Harvard University), Robert Gross(University of Cape Town), Carole L. Wallis, Rosie Mngqibisa, Sandy Nerette Fontain(Gheskio Centers), Cecilia Kanyama, Michael D. Hughes(Virginia Tech), Ann C. Collier(University of Washington), Nagalingeswaran Kumarasamy(University of North Carolina at Chapel Hill), Robert T. Schooley(Unknown), Rochelle P. Walensky(Harvard University), J. Mellors(University of Pittsburgh)
The Lancet HIV
July 29, 2019
Cited by 39


Related Papers